Abstract: Cooling and heating eyeglasses have peltier chips mounted around at least a portion of the perimeter of the lenses that provides a cooling affect that reduces eyestrain and provides cooling relief to the user. A battery pack provides the electrical energy needed to energize the peltier chips. The battery pack is connected to a neck strap that allows the user to comfortably support the batteries. In another embodiment, a plurality of smaller batteries are used and disposed within the frame eliminating the need for an external battery pack. In another embodiment, side shields are also provide with peltier chips to further control the temperature especially around the user's eyes. Because the peltier can also provide heating, a user can also select heating if preferred. The cooling and heating glasses can be used for prevention and treatment of several eye diseases and oculopathies.

Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.

Abstract: A method for treating age related macular degeneration (AMD) using an insulin preparation applied topically to the conjunctival sac of the affected eye. Another aspect of this invention is using antiangiogenic adjuvant therapeutic agents such as bevacizumab, ranibizumab, pegaptanib, etanercept, instilled in to the afflicted eye conjunctival sac with insulin to prevent further formation of new blood vessels, and shrink the existing pathologically formed blood vessels and reduce the edema in wet AMD. This method incorporates putting the patients on low fat diet, aerobic exercise, ketamine-a NMDA blocker, reducing the blood cholesterol using adjuvant therapeutic agents selected from Statins, that are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, (i.e. HMG-Co A) reductase which in turn reduce drusen formation that leads to AMD, combined with insulin ophthalmic drops.

Abstract: A method of treatment of retinitis pigmentosa using a medically effective dose of insulin, IGF-1, and chlorin e6 topically applied to the conjunctival sac of the afflicted eye. The combination of these is very effective in treating retinitis pigmentosa and may be repeated as directed by a medical practitioner. The method includes preparing the dosage and filling an eye dropper with the compound, then having the patient lie in a supine position while administering the dosage. The patient remains in this position for 5 minutes to ensure absorption of the compound. In one embodiment, single use eye droppers are provided to simplify treatment. The particular dosage is adjusted to take individual metabolisms into account. A thorough examination of the patient's eyes should be done prior to treatment.

Abstract: A method for treating age related macular degeneration uses insulin preparation applied topically in a therapeutically effective amount to an affected conjunctival sac of the eye. The topically effective dose is delivered to the fovea centralis and macula lutea. In other embodiments, additional therapeutic, pharmaceutical, biochemical, nutriceutical, biological (monoclonal antibodies and others) agent or compound, and organic and inorganic agents are also applied to the afflicted site through the conjunctival sac and choroidal vascular system of the eye. IGF-1 may be applied as well with or without insulin to treat ARMD.

Abstract: Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.

Abstract: Described herein are transdermal delivery devices composed of at least one resealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.

Abstract: The invention relates to a method of instilling insulin ophthalmic drops in the conjunctival sac for treating retinitis pigmentosa due to any etiological factors both genetic and non genetic. The retinitis pigmentosa is treated with Insulin and/or IGF-I with or without known anti-retinitis pigmentosa therapeutic, pharmaceutical, biochemical, and biological agents or compounds. The invention furthermore uses this method as prophylactic on patients where the patients are predisposed to develop retinitis pigmentosa. The invention additionally treats other oculopathies associated with and/or contributing to retinitis pigmentosa.

Abstract: Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.

Abstract: Described herein are transdermal delivery devices composed of at least one resealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically.

Abstract: Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane.